Loading...
Market
How many countries will approve Clesrovimab for RSV prevention in infants by the end of 2025?
2
Resolution / Starting Odds
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
Global health regulatory announcements and Merck press releases
Story
Merck Announces Positive Phase 2b/3 Results for Clesrovimab in RSV Prevention Trial for Infants
Jul 23, 2024, 12:30 PM
Merck has announced positive topline results from its Phase 2b/3 trial of Clesrovimab (MK-1654), an investigational monoclonal antibody designed to prevent respiratory syncytial virus (RSV) in infants. The antibody-based drug met the main goal of reducing the incidence of lower respiratory infection compared to a placebo in a mid-to-late stage trial. The study, announced on Tuesday, also confirmed the safety profile of the treatment. Merck's announcement highlights the potential of Clesrovimab to protect infants from RSV-related diseases.
View original story
Similar markets
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Less than 50% • 25%
50% to 60% • 25%
60% to 70% • 25%
More than 70% • 25%